DUBLIN – Investors in Lumena Pharmaceuticals Inc. are in line for a big payday, as Shire plc is buying the San Diego-based drug developer for $260 million up front, plus undisclosed milestones linked to the results of clinical trials of one of its pipeline assets – and whatever cash it has left on its balance sheet when the transaction closes.